Global Mirvetuximab Soravtansine Market Strategic Research Report

Scope of the Report

The global Mirvetuximab Soravtansine market size is predicted to grow from US$ 675 million in 2025 to US$ 2,623 million in 2032; it is expected to grow at a CAGR of 16.9% from 2026 to 2032.

Mirvetuximab Soravtansine is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα). It is covalently formed by conjugating a humanized anti-FRα monoclonal antibody, a cleavable linker, and the microtubule inhibitor DM4. The drug can specifically recognize and bind to highly expressed FRα on the surface of tumor cells, release cytotoxic payloads after endocytosis into cells, and precisely kill tumor cells. It is mainly used for the treatment of malignant tumors such as FRα-positive recurrent ovarian cancer. Featuring high targeting ability and strong anti-tumor activity, it provides an important targeted therapeutic option for patients with advanced ovarian cancer.In 2025, global Mirvetuximab Soravtansine production reached approximately 105,000–110,000 vials.

As a globally pioneering and the only approved FRα-targeted ADC drug, Mirvetuximab Soravtansine has established significant clinical and market advantages in the field of platinum-resistant ovarian cancer. Its core value lies in the high efficacy and low toxicity profile brought by its precise targeting mechanism, which effectively addresses the long-unmet clinical needs. The global market is mainly led by the United States, and with successive approvals and commercialization in major markets such as the European Union and China, the product has shown a trend of rapid growth. Supported by priority recommendations in authoritative guidelines, it has further driven continuous improvements in physician prescriptions and patient penetration. In China, the commercialization is led by Huadong Medicine, which has achieved early market access and rapid nationwide coverage through favorable innovative drug policies. The advantages of local channels and academic promotion are gradually unlocking market potential. Looking ahead, its market growth will rely on the continuous penetration of ovarian cancer indications on the one hand, and the potential clinical expansion into other FRα-highly-expressing tumors on the other. Meanwhile, it faces multiple constraints including limited accessibility due to high pricing, the progress of medical insurance coverage, and the development of competing products targeting the same target in the future. Overall, the market is expected to grow steadily while accompanied by uncertainties from competition and policy changes.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Mirvetuximab Soravtansine market?

What factors are driving Mirvetuximab Soravtansine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Mirvetuximab Soravtansine market opportunities vary by end market size?

How does Mirvetuximab Soravtansine break out by Type, by Application?

This report presents a comprehensive overview of the global Mirvetuximab Soravtansine market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Lyophilized Powder for Injection
• Injectable Solution

Segment by Combination Medication

• Mirvetuximab Soravtansine In Combination With Bevacizumab
• Mirvetuximab Soravtansine In Combination With Carboplatin

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• FRα-Positive Recurrent Ovarian Cancer
• Platinum-Resistant Epithelial Ovarian Cancer
• FRα-Highly Expressed Advanced Solid Tumors
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Mirvetuximab Soravtansine market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in FRα-Positive Recurrent Ovarian Cancer, Platinum-Resistant Epithelial Ovarian Cancer, FRα-Highly Expressed Advanced Solid Tumors evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact